Evidence map›Paper›PMID 36009930›Full record

ReviewAntibiotics (Basel, Switzerland)2022

The Structures and Binding Modes of Small-Molecule Inhibitors of

Virgyl Camberlein, Gwenaëlle Jézéquel, Jörg Haupenthal, Anna K H Hirsch

Open access · goldAbstract readReview
In one paragraph

Review in Antibiotics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 18 citations in OpenAlex.

  1. Exploring the Role ofACS infectious diseases · 2026
    Article
  2. Article
  3. Article
  4. Disruption of quorum sensing and biofilm formation in Pseudomonas aeruginosa by plant-based O-methylated flavonoids.International microbiology : the official journal of the Spanish Society for Microbiology · 2025
    Article
  5. Article
  6. Frontiers in microbiology · 2025
    Article
  7. Dual inhibitors ofChemical science · 2024
    Article
  8. A Supramolecular Antibiotic Targeting Drug-ResistantACS applied materials & interfaces · 2024
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Virgyl CamberleinHelmholtz Institute for Pharmaceutical Research Saarland (HIPS)-Helmholtz Centre for Infection Research (HZI), Campus E8.1, 66123 Saarbrücken, Germany.ORCID 0000-0002-7109-8573
Gwenaëlle JézéquelHelmholtz Institute for Pharmaceutical Research Saarland (HIPS)-Helmholtz Centre for Infection Research (HZI), Campus E8.1, 66123 Saarbrücken, Germany.ORCID 0000-0001-8945-8680
Jörg HaupenthalHelmholtz Institute for Pharmaceutical Research Saarland (HIPS)-Helmholtz Centre for Infection Research (HZI), Campus E8.1, 66123 Saarbrücken, Germany.ORCID 0000-0003-3991-2800
Anna K H HirschHelmholtz Institute for Pharmaceutical Research Saarland (HIPS)-Helmholtz Centre for Infection Research (HZI), Campus E8.1, 66123 Saarbrücken, Germany.ORCID 0000-0001-8734-4663
Helmholtz Centre for Infection Research · DE

Funding

CARB-X 05CARB-X0891Federal Ministry of Education and Research 16GW0346
6 · The paper itself

Abstract

Elastase B (LasB) is a zinc metalloprotease and a crucial virulence factor of

Indexed as

antimicrobial resistanceantivirulence therapyelastase LasBPseudomonas aeruginosa infectionsmall-molecule inhibitors

Identifiers

PMID36009930
PMCPMC9404851
OpenAlexW4290037624

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.